

LEUKEMIA IMMUNOPHENOTYPING REPORT

LABORATORY OF FLOW CYTOMETRY, DIVISION OF PATHOLOGY AND LABORATORY MEDICINE
 ROSWELL PARK CANCER INSTITUTE, BUFFALO, NY 14263
 NEW YORK STATE LABORATORY PERMIT #43041401M220; CLIA #33D0171366
 PH. (716) 845-8471; FAX (716) 845-8806, EMAIL: paul.wallace@RoswellPark.org

PATIENT: DONOR, HEALTHY
 ID NUMBER: RP1234
 SPECIMEN: BONE MARROW
 PHYSICIAN: DR. WALLACE
 REPORT DONO0531

DATE/TIME COLLECTED: 5/31/2004 @10:45 am
 DATE/TIME RECEIVED: 5/31/2004 @11:45 am
 DATE/TIME STAINED: 5/31/2004 @12:45 am
 DATE REPORT: 6/1/2004
 LFC FILE: 02124001

DIFFERENTIAL:	PERCENT	#/µL		PERCENT	#/µL
TOTAL CELLS	100.0	25,000		LYMPHOCYTES:	24.9 6,213
% VIABLE	99.8	24,943		TOTAL T CELLS	18.9 4,737
CD45 NEGATIVE	0.2	43		HLADr+ T CELLS	0.9 230
GRANULOCYTES	68.4	17,108		TOTAL B CELLS	1.3 336
MONOCYTES	4.6	1,153		NK CELLS	4.6 1,140
CD45 DIM	2.2	547			

PERCENT GATED 31.4 7,843

T CELL MARKERS:	%GATED	CELLS/µl	%TOTAL
CD2 TOTAL	62.6	4,908	19.63
CD3 TOTAL	60.4	4,737	18.95
CD4 TOTAL	44.4	3,480	13.92
CD5 TOTAL	52.8	4,139	16.56
CD7 TOTAL	31.2	2,446	9.78
CD8 TOTAL	25.6	2,005	8.02
CD7+ CD2+	52.8	4,137	16.55
CD3+ CD4+ CD8-	26.3	2,059	8.23
CD3+ CD4- CD8+	25.0	1,964	7.86
CD4/CD8 RATIO	1.048		

MYELOID MARKERS:	%GATED	CELLS/µl	%TOTAL
CD11b TOTAL	43.3	3,398	13.59
CD11c TOTAL	39.7	3,111	12.44
CD13 TOTAL	31.6	2,475	9.90
CD33 TOTAL	32.9	2,583	10.33
CD14 TOTAL	13.1	1,031	4.12
CD15 TOTAL	3.9	306	1.22
CD16 TOTAL	20.8	1,633	6.53
CD32 TOTAL	26.3	2,065	8.26
CD64 TOTAL	19.7	1,546	6.18

B CELL MARKERS:	%GATED	CELLS/µl	%TOTAL
CD19 TOTAL	4.3	336	1.34
CD20 TOTAL	6.1	482	1.93
CD22 TOTAL	5.6	442	1.77
CD23 TOTAL	7.9	618	2.47
CD11c+ CD20+ CD22+	0.7	54	0.22

OTHER MARKERS	%GATED	CELLS/µl	%TOTAL
CD10 TOTAL	2.3	178	0.71
CD34 TOTAL	1.6	125	0.50
CD38 TOTAL	53.6	4,202	16.81
CD41 TOTAL	17.4	1,368	5.47
CD52 TOTAL	83.8	6,572	26.29
CD56 TOTAL	11.1	869	3.48
CD57 TOTAL	15.5	1,218	4.87
CD71 TOTAL	29.3	2,301	9.20
CD80 TOTAL	0.7	52	0.21
CD138 TOTAL	15.0	1,179	4.71
CD161 TOTAL	22.5	1,761	7.05
CD3- CD57+ TOTAL	14.7	1,150	4.60
CD3+ CD57+ TOTAL	7.0	553	2.21

CD19 GATED MARKERS:	%GATED	CELLS/µl	%TOTAL
CD19+ CD5-	4.0	313	1.25
CD19+ CD5- KAP+ LAM-	2.2	173	0.69
CD19+ CD5- KAP- LAM+	1.3	106	0.42
CD5- KAP/LAM RATIO	1.638		
CD19+ CD5+	0.1	7	0.03
CD19+ CD5+ KAP+ LAM-	0.1	8	0.03
CD19+ CD5+ KAP- LAM+	0.1	8	0.03
CD5+ KAP/LAM RATIO	1.000		

FLOW CYTOMETRIC INTERPRETATION:

Codes for interpretation: br=bright; d=dim expression; h=heterogeneous expression; s=distinct subset; NE=not evaluable

PRELIMINARY REPORT

THE SPECIMEN CELLULARITY IS BELOW WITHIN THE NORMAL REFERENCE RANGE INCREASED FREQUENCY OF EARLY MYELOID PROGENITOR CELLS (LEFT SHIFTED). ERYTHROID PRECURSORS AND A NORMAL CD19+ CD10+ PRE B-CELL POPULATION WAS FOUND. ERYTHROID PRECURSOR AND MICROMEKAKARYOCYTES WERE FOUND. MARKER EXPRESSION IS COMPATIBLE WITH NORMAL EPITOPE INTENSITY. NO FLOW CYTOMETRIC EVIDENCE OF LEUKEMIA.

NORMAL TRILINEAGE HEMATOPOIESIS. THE FLOW CYTOMETRIC AND HISTOPATOLOGY RESULTS ARE CONSISTENT.

PAUL K. WALLACE, Ph.D., DIRECTOR
CARLETON C. STEWART, Ph.D., DIRECTOR

MAURICE BARCOS, M.D., Ph.D.
CONSULTING PATHOLOGIST

DISCLAIMER: THESE TESTS WERE PERFORMED BY CLASS I ANALYTE SPECIFIC REAGENTS PREPARED AS "INHOUSE" TESTS IN COMPLIANCE WITH THE FINAL RULE BY THE FDA IN 21CFR PARTS 209 AND 864 AND REPORTED IN THE FEDERAL REGISTER VOL62 NO.255 PG 62243-62260. THESE TESTS WERE DEVELOPED AND THEIR PERFORMANCE CHARACTERISTICS DEFINED BY THE LABORATORY WITHOUT FDA REVIEW.